Fixed drug eruptions

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Fixed Drug Eruptions (FDEs) are a localized response to medications that typically appear as Well-Demarcated erythematous dusky patches or plaques. They may be solitary, multiple, or generalized. The initial eruption of a FDE appears 1 week Post-Drug exposure, whereas subsequent exposures to the same drug lead to development of lesions within 30 min to 24 h. Despite the number of occurrences, these patches and plaques resolve within 2-3 weeks of discontinuing the offending agent, often leaving Post-Inflammatory hyperpigmentation. NSAIDs (Non-Steroidal Anti-Inflammatory drugs), tetracyclines, Trimethoprim-Sulfamethoxazole, sedatives including barbiturates, benzodiazepines and chlordiazepoxide, and Anti-Convulsants are the most commonly reported drugs causing FDE. Certain drugs have a predilection for causing particular subtypes of FDE, as well as mucosal involvement. Histologically, FDEs present with a vacuolar dermatitis occurring at the Dermo-Epidermal junction. Lymphocyte infiltration and hydropic degeneration of keratinocytes develop over the first 24 h following exposure, which can progress to separation of the dermis and epidermis with subepidermal bullae formation. The immunologic mechanism of FDE involves activation of CD8+ T cells that release interferon gamma, granzymes, and perforins, leading to recruitment of neutrophils, CD4+ T cells, mast cells, and occasionally eosinophils. Diagnosis of FDE is largely clinical and treatment is comprised of discontinuing the offending drug and treating symptoms, such as pruritus and pain. However, if the offending agent is unclear, patch testing or oral Re-Challenge at Sub-Therapeutic doses are the preferred diagnostic tests.

Original languageEnglish (US)
Title of host publicationCutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy
PublisherSpringer-Verlag London Ltd
Pages181-192
Number of pages12
ISBN (Print)9781447167297, 9781447167280
DOIs
StatePublished - Aug 21 2015

Fingerprint

Drug Eruptions
Pharmaceutical Preparations
T-Lymphocytes
Chlordiazepoxide
Convulsants
Granzymes
Tetracyclines
Perforin
Hyperpigmentation
Barbiturates
Neutrophil Infiltration
Sulfamethoxazole Drug Combination Trimethoprim
Dermatitis
Blister
Pruritus
Dermis
Hypnotics and Sedatives
Benzodiazepines
Keratinocytes
Routine Diagnostic Tests

Keywords

  • CD8 T-cells
  • Erythema multiforme (EM)
  • NSAIDs
  • Patch testing
  • Pigmentary incontinence
  • Polysensitivity
  • Targetoid lesions
  • Tetracylines
  • Toxic epidermal necrolysis (TEN)
  • Vacuolar dermatitis

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Immunology and Microbiology(all)

Cite this

Pretzlaff, K. M., Pandya, A. G., & Dominguez, A. R. (2015). Fixed drug eruptions. In Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy (pp. 181-192). Springer-Verlag London Ltd. https://doi.org/10.1007/978-1-4471-6729-7_17

Fixed drug eruptions. / Pretzlaff, Kara M.; Pandya, Amit G.; Dominguez, Arturo R.

Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy. Springer-Verlag London Ltd, 2015. p. 181-192.

Research output: Chapter in Book/Report/Conference proceedingChapter

Pretzlaff, KM, Pandya, AG & Dominguez, AR 2015, Fixed drug eruptions. in Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy. Springer-Verlag London Ltd, pp. 181-192. https://doi.org/10.1007/978-1-4471-6729-7_17
Pretzlaff KM, Pandya AG, Dominguez AR. Fixed drug eruptions. In Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy. Springer-Verlag London Ltd. 2015. p. 181-192 https://doi.org/10.1007/978-1-4471-6729-7_17
Pretzlaff, Kara M. ; Pandya, Amit G. ; Dominguez, Arturo R. / Fixed drug eruptions. Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy. Springer-Verlag London Ltd, 2015. pp. 181-192
@inbook{3b27f191491d4eed915e6230ea44f207,
title = "Fixed drug eruptions",
abstract = "Fixed Drug Eruptions (FDEs) are a localized response to medications that typically appear as Well-Demarcated erythematous dusky patches or plaques. They may be solitary, multiple, or generalized. The initial eruption of a FDE appears 1 week Post-Drug exposure, whereas subsequent exposures to the same drug lead to development of lesions within 30 min to 24 h. Despite the number of occurrences, these patches and plaques resolve within 2-3 weeks of discontinuing the offending agent, often leaving Post-Inflammatory hyperpigmentation. NSAIDs (Non-Steroidal Anti-Inflammatory drugs), tetracyclines, Trimethoprim-Sulfamethoxazole, sedatives including barbiturates, benzodiazepines and chlordiazepoxide, and Anti-Convulsants are the most commonly reported drugs causing FDE. Certain drugs have a predilection for causing particular subtypes of FDE, as well as mucosal involvement. Histologically, FDEs present with a vacuolar dermatitis occurring at the Dermo-Epidermal junction. Lymphocyte infiltration and hydropic degeneration of keratinocytes develop over the first 24 h following exposure, which can progress to separation of the dermis and epidermis with subepidermal bullae formation. The immunologic mechanism of FDE involves activation of CD8+ T cells that release interferon gamma, granzymes, and perforins, leading to recruitment of neutrophils, CD4+ T cells, mast cells, and occasionally eosinophils. Diagnosis of FDE is largely clinical and treatment is comprised of discontinuing the offending drug and treating symptoms, such as pruritus and pain. However, if the offending agent is unclear, patch testing or oral Re-Challenge at Sub-Therapeutic doses are the preferred diagnostic tests.",
keywords = "CD8 T-cells, Erythema multiforme (EM), NSAIDs, Patch testing, Pigmentary incontinence, Polysensitivity, Targetoid lesions, Tetracylines, Toxic epidermal necrolysis (TEN), Vacuolar dermatitis",
author = "Pretzlaff, {Kara M.} and Pandya, {Amit G.} and Dominguez, {Arturo R.}",
year = "2015",
month = "8",
day = "21",
doi = "10.1007/978-1-4471-6729-7_17",
language = "English (US)",
isbn = "9781447167297",
pages = "181--192",
booktitle = "Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy",
publisher = "Springer-Verlag London Ltd",

}

TY - CHAP

T1 - Fixed drug eruptions

AU - Pretzlaff, Kara M.

AU - Pandya, Amit G.

AU - Dominguez, Arturo R.

PY - 2015/8/21

Y1 - 2015/8/21

N2 - Fixed Drug Eruptions (FDEs) are a localized response to medications that typically appear as Well-Demarcated erythematous dusky patches or plaques. They may be solitary, multiple, or generalized. The initial eruption of a FDE appears 1 week Post-Drug exposure, whereas subsequent exposures to the same drug lead to development of lesions within 30 min to 24 h. Despite the number of occurrences, these patches and plaques resolve within 2-3 weeks of discontinuing the offending agent, often leaving Post-Inflammatory hyperpigmentation. NSAIDs (Non-Steroidal Anti-Inflammatory drugs), tetracyclines, Trimethoprim-Sulfamethoxazole, sedatives including barbiturates, benzodiazepines and chlordiazepoxide, and Anti-Convulsants are the most commonly reported drugs causing FDE. Certain drugs have a predilection for causing particular subtypes of FDE, as well as mucosal involvement. Histologically, FDEs present with a vacuolar dermatitis occurring at the Dermo-Epidermal junction. Lymphocyte infiltration and hydropic degeneration of keratinocytes develop over the first 24 h following exposure, which can progress to separation of the dermis and epidermis with subepidermal bullae formation. The immunologic mechanism of FDE involves activation of CD8+ T cells that release interferon gamma, granzymes, and perforins, leading to recruitment of neutrophils, CD4+ T cells, mast cells, and occasionally eosinophils. Diagnosis of FDE is largely clinical and treatment is comprised of discontinuing the offending drug and treating symptoms, such as pruritus and pain. However, if the offending agent is unclear, patch testing or oral Re-Challenge at Sub-Therapeutic doses are the preferred diagnostic tests.

AB - Fixed Drug Eruptions (FDEs) are a localized response to medications that typically appear as Well-Demarcated erythematous dusky patches or plaques. They may be solitary, multiple, or generalized. The initial eruption of a FDE appears 1 week Post-Drug exposure, whereas subsequent exposures to the same drug lead to development of lesions within 30 min to 24 h. Despite the number of occurrences, these patches and plaques resolve within 2-3 weeks of discontinuing the offending agent, often leaving Post-Inflammatory hyperpigmentation. NSAIDs (Non-Steroidal Anti-Inflammatory drugs), tetracyclines, Trimethoprim-Sulfamethoxazole, sedatives including barbiturates, benzodiazepines and chlordiazepoxide, and Anti-Convulsants are the most commonly reported drugs causing FDE. Certain drugs have a predilection for causing particular subtypes of FDE, as well as mucosal involvement. Histologically, FDEs present with a vacuolar dermatitis occurring at the Dermo-Epidermal junction. Lymphocyte infiltration and hydropic degeneration of keratinocytes develop over the first 24 h following exposure, which can progress to separation of the dermis and epidermis with subepidermal bullae formation. The immunologic mechanism of FDE involves activation of CD8+ T cells that release interferon gamma, granzymes, and perforins, leading to recruitment of neutrophils, CD4+ T cells, mast cells, and occasionally eosinophils. Diagnosis of FDE is largely clinical and treatment is comprised of discontinuing the offending drug and treating symptoms, such as pruritus and pain. However, if the offending agent is unclear, patch testing or oral Re-Challenge at Sub-Therapeutic doses are the preferred diagnostic tests.

KW - CD8 T-cells

KW - Erythema multiforme (EM)

KW - NSAIDs

KW - Patch testing

KW - Pigmentary incontinence

KW - Polysensitivity

KW - Targetoid lesions

KW - Tetracylines

KW - Toxic epidermal necrolysis (TEN)

KW - Vacuolar dermatitis

UR - http://www.scopus.com/inward/record.url?scp=84955369651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955369651&partnerID=8YFLogxK

U2 - 10.1007/978-1-4471-6729-7_17

DO - 10.1007/978-1-4471-6729-7_17

M3 - Chapter

SN - 9781447167297

SN - 9781447167280

SP - 181

EP - 192

BT - Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy

PB - Springer-Verlag London Ltd

ER -